Goldman Sachs
SION

Goldman Sachs’s Sionna Therapeutics SION Stock Holding History

Goldman Sachs’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
263,174
+226,905
+626% +$8.66M ﹤0.01% 3032
2025
Q4 		$1.49M Buy
36,269
+24,091
+198% +$914K ﹤0.01% 4837
2025
Q3 		$358K Sell
12,178
-33,870
-74% -$737K ﹤0.01% 5675
2025
Q2 		$799K Sell
46,048
-17,693
-28% -$232K ﹤0.01% 4857
2025
Q1 		$667K Buy
+63,741
New +$1.04M ﹤0.01% 4997

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's SION Position: Q1 2026 in Review

Goldman Sachs increased its Sionna Therapeutics (SION) stake by 626% in Q1 2026, buying an estimated $8.66M and bringing the position to 263,174 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

Goldman Sachs first reported a position in SION in Q1 2025 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Goldman Sachs held 263,174 shares of Sionna Therapeutics worth $10.6M as of Q1 2026.
  • Goldman Sachs bought 226,905 Sionna Therapeutics shares in Q1 2026, an estimated $8.66M.
  • Sionna Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3032 holding.
  • Goldman Sachs first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.